Related Experiment Video
Updated: Jul 15, 2026
04:36
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Flt3-dependent transformation by inactivating c-Cbl mutations in AML.
Bülent Sargin1, Chunaram Choudhary, Nicola Crosetto
1Department of Medicine, Hematology and Oncology, and Interdisciplinary Center for Clinical Research, University Hospital Münster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany.
Blood
|April 21, 2007
Summary
In acute myeloid leukemia (AML), c-Cbl negatively regulates Flt3 signaling. Mutations in c-Cbl disrupt Flt3 regulation, promoting leukemic transformation by altering receptor signaling and promoting cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Flt3 mutations are common in acute myeloid leukemia (AML).
- The role of wild-type Flt3 and its regulators in AML is less understood.
- c-Cbl is a key regulator of receptor tyrosine kinase (RTK) signaling.
Purpose of the Study:
- To investigate the role of c-Cbl in Flt3 signal transduction.
- To determine c-Cbl's involvement in myeloid transformation.
- To explore the impact of c-Cbl mutations on Flt3 signaling in AML.
Main Methods:
- Analyzed c-Cbl interaction with Flt3.
- Assessed Flt3 ubiquitylation and internalization using dominant-negative c-Cbl (Cbl-70Z).
- Sequenced c-Cbl in AML bone marrow and analyzed a specific mutation (Cbl-R420Q).
- Evaluated the effect of mutant c-Cbl on Flt3 signaling and cell transformation in 32Dcl3 cells.
Main Results:
- c-Cbl physically interacts with and is phosphorylated by Flt3.
- Dominant-negative c-Cbl inhibits Flt3 ubiquitylation and internalization.
- A novel c-Cbl mutation (Cbl-R420Q) found in AML inhibits Flt3 internalization and ubiquitylation.
- Mutant c-Cbl proteins induce cytokine-independent cell growth and survival, altering Flt3 signaling dynamics.
Conclusions:
- c-Cbl plays a crucial role in modulating Flt3 signaling.
- Mutational inactivation of negative RTK regulators like c-Cbl represents a novel mechanism for leukemic transformation in AML.
- These findings highlight c-Cbl as a potential therapeutic target in AML.
